Seattle Genetics (SGEN) Misses Q4 EPS by 32c, Revenues Beat; Offers FY19 Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Seattle Genetics Reports Fourth Quarter and Full Year 2018 Financial Results
February 7, 2019 4:02 PM EST-ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $476.9 Million in 2018, Including $132.1 Million in the Fourth Quarter-
-ADCETRIS Approved by FDA in Combination with Chemotherapy for Frontline CD30-Expressing PTCL-
-Top-line Data from Enfortumab Vedotin Pivotal Trial in Metastatic Urothelial Cancer Expected in the First Quarter of 2019-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc.(Nasdaq: SGEN) today reported financial results for the fourth quarter and year ended December31, 2018. The company also... More
